Halma HY Pre-tax Profit Down

Halma plc (HLMA.L) reported that its profit before taxation for the six-month ended 30 September 2020 declined 9% to 96.3 million pounds from 105.8 million pounds in the prior year.

Adjusted profit before taxation decreased 5% to 122.0 million pounds from the previous year.

Profit attributable to equity shareholders was 77.3 million pounds, down from 85.0 million pounds in the prior year. Earnings per share from continuing operation were 20.37 pence compared to 22.40 pence in the prior year.

Revenue for the period decreased 5% to 618.4 million pounds from 653.7 million pounds last year.

The reported revenue decline included an 11% reduction in organic constant currency revenue, a 6% contribution from acquisitions completed last year, and a small negative currency translation effect of 0.4%.

The Board has declared an increase of 5% in the interim dividend to 6.87 pence per share compared to 6.54 pence per share paid last year. The interim dividend will be paid on 5 February 2021 to shareholders on the register on 29 December 2020.

The company now expects adjusted profit before tax for fiscal year 2020/21 to be around 5% below fiscal year 2019/20, compared to prior guidance of 5% to 10% below fiscal year 2019/20.

The company said that, from 1 April 2021, it will operate and report as three sectors to reflect the increasing importance of environmental and healthcare issues and align with its purpose and focus on safety, health and environmental markets.

The company noted that it will combine its two Safety sectors under a single Sector CEO and appoint a separate Sector CEO and M&A team for each of its Medical and Environmental & Analysis sectors.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT